Darrell S Rigel
Overview
Explore the profile of Darrell S Rigel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
105
Citations
1208
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Rigel D, Whitaker J, Skelsey M, Peck G, Howell M, Jansen B
J Invest Dermatol
. 2021 Jul;
142(1):232-234.
PMID: 34273350
No abstract available.
12.
13.
W Marson J, Litchman G, Rigel D
J Drugs Dermatol
. 2021 Feb;
20(2):215-223.
PMID: 33538568
Background: COVID-19 has had significant negative economic ramifications on dermatologic care delivery, including curtailing live on-site physician-pharmaceutical-representative interactions (PPRI). Objective: To determine the impact of COVID-19 and pandemic regulations on...
14.
The magnitude of COVID-19's effect on the timely management of melanoma and nonmelanoma skin cancers
W Marson J, Maner B, Harding T, Meisenheimer Vii J, Solomon J, Leavitt M, et al.
J Am Acad Dermatol
. 2021 Jan;
84(4):1100-1103.
PMID: 33482258
No abstract available.
15.
Litchman G, W Marson J, Rigel D
J Am Acad Dermatol
. 2020 Oct;
84(2):576-579.
PMID: 33010326
No abstract available.
16.
Litchman G, Teplitz R, W Marson J, Rigel D
J Am Acad Dermatol
. 2020 Sep;
85(4):976-979.
PMID: 32926981
No abstract available.
17.
W Marson J, Litchman G, Rigel D
J Am Acad Dermatol
. 2020 Sep;
84(6):1734-1735.
PMID: 32871162
No abstract available.
18.
Litchman G, Rigel D
J Am Acad Dermatol
. 2020 May;
83(2):685-686.
PMID: 32422226
No abstract available.
19.
Litchman G, Fitzgerald A, Kurley S, Cook R, Rigel D
Curr Med Res Opin
. 2020 May;
36(8):1295-1300.
PMID: 32372702
To determine how results from a prognostic 40-gene expression profiling (40-GEP) test would impact clinician management decisions and how their choices would align with a National Comprehensive Cancer Network (NCCN)...
20.
Wysong A, Newman J, Covington K, Kurley S, Ibrahim S, Farberg A, et al.
J Am Acad Dermatol
. 2020 Apr;
84(2):361-369.
PMID: 32344066
Background: Current staging systems for cutaneous squamous cell carcinoma (cSCC) have limited positive predictive value for identifying patients who will experience metastasis. Objective: To develop and validate a gene expression...